A Novel, Targeted therapy for
Triple Negative Breast Cancer
and other aggressive cancers
![](https://pannextherapeutics.com/wp-content/uploads/2022/01/img1-423x480.png)
PANNEX Therapeutics is at the forefront of developing Pannexin 1 channel (Panx1) blockers, a new class of cancer drugs that block multiple pathways to enhance the immune system’s response, curb tumor growth, and minimize the spread of metastases.
Discover our science
Pannexin 1
The Pannexin 1 channel (Panx1), a recently discovered and validated pharmacological target, is overexpressed in many cancer types and linked to poor clinical outcome.
ScienceOur team
![](https://pannextherapeutics.com/wp-content/uploads/2022/01/david.png)
David Bravo PhD
Chief Executive Officer &
Co-founder
Pannexin 1 research leader with more than a decade of success in drug discovery and innovation
![](https://pannextherapeutics.com/wp-content/uploads/2022/01/thomas.png)
Thomas Gerlach PhD
Chief Strategic Officer &
Co-founder
Biochemist with over 30 years of experience in global drug development, commercialization and venture capital
![](https://pannextherapeutics.com/wp-content/uploads/2022/01/gerhard.png)
Gerhard Gross PhD
Chief Scientific Officer &
Co-founder
Chemist with 30 years of experience in drug discovery and development - 14 FDA - approved drugs